Table 5 Experimental studies testing the efficacy of MSC-derived EVs in UUO-CKD
Type of model | Species | Intervention | Administration methods | Main findings | Reference |
|---|---|---|---|---|---|
In vivo; in vitro, tubular epithelial cells | Mouse | Allogenic bone marrow MSC-derived EVs | Intravenous | • EVs preserved renal function • Decreased tubular injury and epithelial to mesenchymal transition | He et al. 2015 [57] |
In vivo; in vitro; human umbilical vein endothelial cells | Mouse | Allogenic kidney MSC-derived EVs | Intravenous | • EVs ameliorated endothelial to mesenchymal transition and improved proliferation • Prevented inflammatory cell infiltration, enhanced proliferation of tubular cells, and decreased apoptosis and microvascular rarefaction | Choi et al. 2015 [58] |